Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0132


Trastuzumab for small HER2-positive breast cancer? Uncertainty and new research directions

Ioannis Makris, M.D.

Affiliation: 2nd Surgical Department, Aristotle University of Thessaloniki , "G, Gennimatas" General Hospital , Thessaloniki , Greece .

Tel +302310992567,


Since there is no abstract available we provide the first paragraph

Although cure is achievable in small breast cancer, a subgroup of women faces a recurrence risk. This article discusses advances and limitations in predicting this high-risk group, whether trastuzumab for small, HER2-positive tumors can reduce recurrence risk. New research directions including cancer stem cells and molecular networks are also described.

(Citation: Gastric & Breast Cancer 2010; 9(3): 106-109)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 9 June 2010